June 12, 2025 07:00 AM EDT
R&D

Schrödinger says ear­ly MALT1 da­ta could lay 'great foun­da­tion' for com­bos

Nicole DeFeudis

Editor

Schrödinger said its ex­per­i­men­tal MALT1 in­hibitor showed ear­ly signs of safe­ty and ef­fi­ca­cy in an on­go­ing Phase 1 tri­al.

The com­pa­ny al­so said the da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Cure­Vac CEO on BioN­Tech deal: Come to­geth­er 'rather than fight­ing each oth­er in court'

Kennedy's vac­cine doubts hinge on 'in­ert' place­bos, but ex­perts say he mis­un­der­stands the sci­ence

Ex­clu­sive: Kennedy picks for vac­cine ad­vi­so­ry board were paid ex­perts against Mer­ck in civ­il cas­es

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times